Missed opportunities for hepatitis c testing in opioid treatment programs

Jemima A. Frimpong

Research output: Contribution to journalArticle

Abstract

HCV has surpassed HIV as a cause of death in the United States and is particularly prevalent among injection drug users. I examined the availability of on-site HCV testing in a nationally representative sample of opioid treatment programs. Nearly 68% of these programs had the staff required for HCV testing, but only 34% offered on-site testing. Availability of on-site testing increased only slightly with the proportion of injection drug users among clients. The limited HCV testing services in opioid treatment programs is a key challenge to reducing HCV in the US population.

Original languageEnglish (US)
Pages (from-to)1028-1030
Number of pages3
JournalAmerican journal of public health
Volume103
Issue number6
DOIs
StatePublished - Jun 2013

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Fingerprint Dive into the research topics of 'Missed opportunities for hepatitis c testing in opioid treatment programs'. Together they form a unique fingerprint.

  • Cite this